文献速递基础与转化研究流行病学与生物统计组学、生物样本库与精准医学

内皮细胞相关遗传变异识别对低密度脂蛋白胆固醇敏感且从他汀强化降脂中获益更大的个体

Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering.
PubMed 文献 · Nat Med · 2025-02-26

研究从全基因组显著冠心病相关单核苷酸多态性中筛选影响内皮细胞功能的变异,构建35个变异的多基因风险评分(EC PRS),在UK Biobank、JUPITER和FOURIER三个队列中验证其与心血管疾病风险的关联及LDL-C的修饰作用。结果显示EC PRS与冠心病风险独立相关,LDL-C水平显著修饰该风险,高EC PRS个体从降LDL-C治疗中获得的相对风险降低幅度更大。

要点

  • EC PRS由35个内皮细胞相关变异构成,与 incident CAD 风险独立相关(每1个标准差aHR 1.24)。
  • LDL-C水平显著修饰EC PRS与CAD风险的关联(交互P=0.004)。
  • 高EC PRS个体从降LDL-C治疗中获得的相对风险降低更大(一级预防68% vs 29%,交互P=0.02)。

核心结论

  • EC PRS量化了一个目前临床实践未捕获的独立CAD风险轴,并识别出对LDL-C致动脉粥样硬化效应更敏感、可能从强化降LDL-C治疗中获得更大益处的个体。

研究设计与样本

  • 研究分析了与冠心病全基因组显著相关的单核苷酸多态性,筛选出影响内皮细胞功能的变异,构建了包含35个单核苷酸多态性的多基因风险评分(EC PRS)。
  • 在三个队列中检验EC PRS与 incident 心血管疾病风险的关联:UK Biobank一级预防人群(n=348,967)、测试他汀的JUPITER一级预防队列(n=8,749)和测试PCSK9抑制剂的FOURIER二级预防队列(n=14,298)。

主要发现

  • 在UK Biobank中,EC PRS与 incident CAD 风险独立相关(每1个标准差aHR 1.24,95% CI 1.21-1.26,P < 2×10^-16)。
  • LDL-C浓度显著修饰该风险:LDL-C为150 mg/dl时每1个标准差aHR 1.26(95% CI 1.22-1.30),LDL-C为50 mg/dl时aHR 1.00(95% CI 0.85-1.16),交互P=0.004。
  • 在一级预防队列中,高EC PRS个体降LDL-C治疗的相对风险降低为68%(HR 0.32,95% CI 0.18-0.59),低或中等EC PRS个体为29%(HR 0.71,95% CI 0.52-0.95),交互P=0.02。
  • 在二级预防队列中,高EC PRS个体降LDL-C治疗的相对风险降低为33%(HR 0.67,95% CI 0.53-0.83),低或中等EC PRS个体为8%(HR 0.92,95% CI 0.82-1.03),交互P=0.01。

关键数值与推荐

  • EC PRS由35个单核苷酸多态性构成。
  • UK Biobank中EC PRS每1个标准差与 incident CAD 的aHR为1.24(95% CI 1.21-1.26),P < 2×10^-16。
  • LDL-C 150 mg/dl时EC PRS每1个标准差aHR 1.26(95% CI 1.22-1.30),LDL-C 50 mg/dl时aHR 1.00(95% CI 0.85-1.16),交互P=0.004。
  • 一级预防队列中高EC PRS个体相对风险降低68%(HR 0.32,95% CI 0.18-0.59),低或中等EC PRS个体降低29%(HR 0.71,95% CI 0.52-0.95),交互P=0.02。
  • 二级预防队列中高EC PRS个体相对风险降低33%(HR 0.67,95% CI 0.53-0.83),低或中等EC PRS个体降低8%(HR 0.92,95% CI 0.82-1.03),交互P=0.01。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The role of endothelial cell (EC) dysfunction in contributing to an individual's susceptibility to coronary atherosclerosis and how low-density lipoprotein cholesterol (LDL-C) concentrations might modify this relationship have not been previously studied. Here, from an examination of genome-wide significant single nucleotide polymorphisms associated with coronary artery disease (CAD), we identified variants with effects on EC function and constructed a 35 single nucleotide polymorphism polygenic risk score comprising these EC-specific variants (EC PRS). The association of the EC PRS with the risk of incident cardiovascular disease was tested in 3 cohorts: a primary prevention population in the UK Biobank (UKBB; n = 348,967); a primary prevention cohort from a trial that tested a statin (JUPITER, n = 8,749); and a secondary prevention cohort that tested a PCSK9 inhibitor (FOURIER, n = 14,298). In the UKBB, the EC PRS was independently associated with the risk of incident CAD (adjusted hazard ratio (aHR) per 1 s.d. of 1.24 (95% CI 1.21-1.26), P < 2 × 10-16). Moreover, LDL-C concentration significantly modified this risk: the aHR per 1 s.d. was 1.26 (1.22-1.30) when LDL-C was 150 mg dl-1 but 1.00 (0.85-1.16) when LDL-C was 50 mg dl-1 (Pinteraction = 0.004). The clinical benefit of LDL-C lowering was significantly greater in individuals with a high EC PRS than in individuals with low or intermediate EC PRS, with relative risk reductions of 68% (HR 0.32 (0.18-0.59)) versus 29% (HR 0.71 (0.52-0.95)) in the primary prevention cohort (Pinteraction = 0.02) and 33% (HR 0.67 (0.53-0.83)) versus 8% (HR 0.92 (0.82-1.03)) in the secondary prevention cohort (Pinteraction = 0.01). We conclude that EC PRS quantifies an independent axis of CAD risk that is not currently captured in medical practice and identifies individuals who are more sensitive to the atherogenic effects of LDL-C and who would potentially derive substantially greater benefit from aggressive LDL-C lowering.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Marston NA, Kamanu FK, Melloni GEM, et al. Endothelial cell-related genetic variants identify LDL cholesterol-sensitive individuals who derive greater benefit from aggressive lipid lowering. Nat Med. 2025. PMID: 40011692. doi:10.1038/s41591-025-03533-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。